meta
|
evidence
oncology
Living systematic review and meta-analysis
multiple myeloma - 1st line (L1)
1
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus lenalidomide and dexamethasone
versus all
vs Immunosuppressant
vs lenalidomide based treatment
vs lenalidomide and dexamethasone
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
Evidence gap map
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
pembrolizumab based treatment
pembrolizumab plus lenalidomide and dexamethasone
Comparator:
vs lenalidomide and dexamethasone;
Risk of bias:
low;
some concerns;
high;
NA;